During last night’s earnings conference call, Chromadex management commented on recent clinical studies involving NAD+ boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Reviews) and Parkinson’s. The following are key quotes:

CEO Rob Fried:

“The science on Niagen (NR) is very promising, which Frank will discuss in a moment.

I mentioned the recently published clinical study on Parkinson’s, which will include two additional studies by the same group of researchers.

In Phase II study, 400 patients will be given a gram of NR per day, while the Phase III study will administer the highest daily dose of NR in any clinical study to-date, at 3,000 milligrams per day”

Executive Chairman Frank Jaksch:

“Moving onto new and exciting research, I’ll briefly highlight two clinical NR studies that we’ll register recently. These built on our recent peer-reviewed, published clinical study on Parkinson’s disease or PD patients that Andrew reviewed in detail last quarter.

The Phase I study or NAD park study showed NR supplementation significantly increased cerebral NAD levels, improved some measures of motor function, and decreased inflammatory cytokines in PD patients. The results of the study, nominate NR as a potential neural protective therapy for PD patients, warranting further Investigation in larger trials.

A second study, the NOPARK study, is underway with the same group of researchers. The study will recruit 400 PD patients and administer 1,000 milligrams of NR daily for 52-weeks, the same daily doses, to smaller Phase I study.

Finally, a third study, the NR-SAFE study, began recruiting a couple of weeks ago. The objective is to determine the safety and tolerability of NR at a daily dose of 3,000 milligrams in 20 individuals with PD to enable clinical studies assessing higher doses. The safety and tolerability of NR doses up to 2,000 milligrams daily have been tested in healthy humans with no signs of toxicity. So this is the highest dose tested in a clinical study to-date.

All three clinical trials are randomized double-blinded placebo controlled and paralleled design studies. This is an exciting area of research on NR, and we look forward to learning more”

Related:

  • New Phase 1 Clinical Trial Results Show B3 Vitamin Nicotinamide Riboside (NR) as a Potential Neuroprotective Therapy for Parkinson`s Disease. Why is This Important? (Link)
  • Parkinson’s Site Examines the Promising New Human Trial Results Using Supplement Nicotinamide Riboside (NR) (Link)
  • Should Those Suffering from Parkinson’s Disease Supplement with Nicotinamide Riboside (NR)? (Link)
  • “NR” and Alzheimer’s (FAQs)
  • Nicotinamide Riboside “NR” (FAQs) (Reviews) (Podcasts)

FOLLOW us on Twitter @RaisingNAD